{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T12:22:20Z","timestamp":1753273340383},"reference-count":27,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1097\/ftd.0000000000000098","type":"journal-article","created":{"date-parts":[[2014,5,15]],"date-time":"2014-05-15T13:43:54Z","timestamp":1400161434000},"page":"734-738","source":"Crossref","is-referenced-by-count":11,"title":["CYP2B6 516G>T (rs3745274) and Smoking Status Are Associated With Efavirenz Plasma Concentration in a Serbian Cohort of HIV Patients"],"prefix":"10.1097","volume":"36","author":[{"given":"Adeniyi","family":"Olagunju","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Siccardi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alieu","family":"Amara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Djordje","family":"Jevtovic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jovana","family":"Kusic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Owen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gordana","family":"Dragovic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-9-20210129","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1097\/00002030-200101050-00011","article-title":". Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients.","volume":"15","author":"Marzolini","year":"2001","journal-title":"AIDS"},{"key":"R2-9-20210129","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1177\/135965350801300507","article-title":". Factors influencing efavirenz and nevirapine plasma concentration: effect of ethnicity, weight and co-medication.","volume":"13","author":"Stohr","year":"2008","journal-title":"Antivir Ther"},{"key":"R3-9-20210129","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1124\/jpet.103.049601","article-title":". The cytochrome P4502B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIVAIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity.","volume":"306","author":"Ward","year":"2003","journal-title":"J Pharmacol Exp Ther"},{"key":"R4-9-20210129","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1124\/jpet.106.112136","article-title":". Relative activation of human pregnane X receptor versus constitutive androstane receptor defines distinct classes of CYP2B6 and CYP3A4 inducers.","volume":"320","author":"Faucette","year":"2007","journal-title":"J Pharmacol Exp Ther"},{"key":"R5-9-20210129","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1124\/jpet.105.098160","article-title":". Differential regulation of hepatic CYP2B6 and CYP3A4 genes by constitutive androstane receptor but not pregnane X receptor.","volume":"317","author":"Faucette","year":"2006","journal-title":"J Pharmacol Exp Ther"},{"key":"R6-9-20210129","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1097\/FTD.0b013e318274197e","article-title":". Correlates of efavirenz exposure in Chilean patients affected with human immunodeficiency virus reveals a novel association with a polymorphism in the constitutive androstane receptor.","volume":"35","author":"Cortes","year":"2013","journal-title":"Ther Drug Monit"},{"key":"R7-9-20210129","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1093\/jac\/dkn029","article-title":". Impact of CYP2B6 983T C polymorphism on non-nucleoside reverse transcriptase inhibitor plasma concentrations in HIV-infected patients.","volume":"61","author":"Wyen","year":"2008","journal-title":"J Antimicrob Chemother"},{"key":"R8-9-20210129","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1097\/FPC.0b013e328363176f","article-title":". High predictive value of CYP2B6 SNPs for steady-state plasma efavirenz levels in South African HIVAIDS patients.","volume":"23","author":"Swart","year":"2013","journal-title":"Pharmacogenet Genomics"},{"key":"R9-9-20210129","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1097\/FPC.0b013e32835a450b","article-title":". Genome-wide association study of plasma efavirenz pharmacokinetics in AIDS Clinical Trials Group protocols implicates several CYP2B6 variants.","volume":"22","author":"Holzinger","year":"2012","journal-title":"Pharmacogenet Genomics"},{"key":"R10-9-20210129","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1186\/1471-2350-13-112","article-title":". PXR and CAR single nucleotide polymorphisms influence plasma efavirenz levels in South African HIVAIDS patients.","volume":"13","author":"Swart","year":"2012","journal-title":"BMC Med Genet"},{"key":"R11-9-20210129","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1124\/dmd.110.034504","article-title":". Cigarette smoke extract induces CYP2B6 through constitutive androstane receptor in hepatocytes.","volume":"39","author":"Washio","year":"2011","journal-title":"Drug Metab Dispos"},{"key":"R12-9-20210129","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.taap.2003.12.027","article-title":". PXR (NR1I2): splice variants in human tissues, including brain, and identification of neurosteroids and nicotine as PXR activators.","volume":"199","author":"Lamba","year":"2004","journal-title":"Toxicol Appl Pharmcol"},{"key":"R13-9-20210129","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1093\/jac\/dkr272","article-title":". Cytochrome P450 2B6 (CYP2B6) and constitutive androstane receptor (CAR) polymorphisms are associated with early discontinuation of efavirenz-containing regimens.","volume":"66","author":"Wyen","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"R14-9-20210129","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1097\/00002030-199004000-00007","article-title":"HIV infection, cigarette smoking and CD4 T-lymphocyte counts: preliminary results from the San Francisco Mens Health Study.","volume":"4","author":"Royce","year":"1990","journal-title":"AIDS"},{"key":"R15-9-20210129","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/jhg.2009.20","article-title":". A pharmacogenetic study of CD4 recovery in response to HIV antiretroviral therapy in two South African population groups.","volume":"54","author":"Parathyras","year":"2009","journal-title":"J Hum Genet"},{"key":"R16-9-20210129","doi-asserted-by":"crossref","first-page":"D48","DOI":"10.1093\/nar\/gks1236","article-title":". Ensembl 2013.","volume":"41","author":"Flicek","year":"2013","journal-title":"Nucleic Acids Res"},{"key":"R17-9-20210129","doi-asserted-by":"crossref","first-page":"547","DOI":"10.2217\/14622416.8.6.547","article-title":". Impact of CYP2B6 polymorphism on hepatic efavirenz metabolism in vitro.","volume":"8","author":"Desta","year":"2007","journal-title":"Pharmacogenomics"},{"key":"R18-9-20210129","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1124\/jpet.107.133306","article-title":". Aberrant splicing caused by single nucleotide polymorphism c.516G T Q172H, a marker of CYP2B66, is responsible for decreased expression and activity of CYP2B6 in liver.","volume":"325","author":"Hofmann","year":"2008","journal-title":"J Pharmacol Exp Ther"},{"key":"R19-9-20210129","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1146\/annurev.pharmtox.41.1.123","article-title":"Phenobarbital response elements of cytochrome P450 genes and nuclear receptors.","volume":"41","author":"Sueyoshi","year":"2001","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"R20-9-20210129","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1124\/dmd.31.1.7","article-title":"Constitutive androstane receptor and pregnane X receptor gene expression in human liver: interindividual variability and correlation with CYP2B6 mRNA levels.","volume":"31","author":"Chang","year":"2003","journal-title":"Drug Metab Dispos"},{"key":"R21-9-20210129","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/S0028-3908(03)00136-9","article-title":". Smoking, alcoholism and genetic polymorphisms alter CYP2B6 levels in human brain.","volume":"45","author":"Miksys","year":"2003","journal-title":"Neuropharmacology"},{"key":"R23-9-20210129","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1093\/ajcp\/107.1.64","article-title":". Smoking, alcohol consumption, and leukocyte counts.","volume":"107","author":"Parry","year":"1997","journal-title":"Am J Clin Pathol"},{"key":"R24-9-20210129","first-page":"301","article-title":". The effect of cigarette smoking on lymphocyte subsets and progression to AIDS in a cohort of homosexual men.","volume":"15","author":"Craib","year":"1992","journal-title":"Clin Invest Med"},{"key":"R25-9-20210129","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1164\/ajrccm\/139.6.1446","article-title":". The effects of cigarette smoking on T cell subsets. A population-based survey of healthy caucasians.","volume":"139","author":"Tollerud","year":"1989","journal-title":"Am Rev Respir Dis"},{"key":"R26-9-20210129","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1086\/522175","article-title":". Successful efavirenz dose reduction in HIV type 1-infected individuals with cytochrome P4502B66 and 26.","volume":"45","author":"Gatanaga","year":"2007","journal-title":"Clin Infect Dis"},{"key":"R27-9-20210129","first-page":"999","article-title":"Would a CYP2B6 test help HIV patients being treated with efavirenz Pharmacogenomics.","volume":"14","author":"Sukasem","year":"2013","journal-title":""},{"key":"R28-9-20210129","doi-asserted-by":"crossref","first-page":"641089","DOI":"10.1155\/2013\/641089","article-title":"Scientific challenges and implementation barriers to translation of pharmacogenomics in clinical practice.","volume":"2013","author":"Lam","year":"2013","journal-title":"ISRN Pharmacol"}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000000098","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,13]],"date-time":"2023-07-13T04:38:47Z","timestamp":1689223127000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00007691-201412000-00009"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12]]},"references-count":27,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2014]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000000098","relation":{},"ISSN":["0163-4356"],"issn-type":[{"value":"0163-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2014,12]]}}}